Want to see AU:TRJ full AI Analyst Report?
TRJ Stock Chart & Stats
AU$0.39
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.39
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.97
Previous CloseN/A
Volume3.68K
Average Volume (3M)21.61K
Market Cap
AU$31.34M
Enterprise ValueAU$94.80M
Total Cash (Recent Filing)AU$12.78M
Total Debt (Recent Filing)AU$69.37M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding152,863,630
10 Day Avg. Volume15,523
30 Day Avg. Volume21,606
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.03
Price to Sales (P/S)0.65
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.83Price Target Upside111.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$181.07M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables BusinessTrajan’s core revenue comes from consumables and components used in routine lab workflows, creating repeat purchase behavior and predictable revenue. This business model supports steady demand from recurring testing, improving revenue stability and cash visibility over a multi-month horizon.
Consistent Top-line GrowthThe company has reported modest but positive revenue growth, indicating continued market adoption of its products across life sciences, environmental and industrial labs. Sustained mid-single-digit growth supports scale benefits and provides runway to improve margins if operational efficiency is addressed.
Stable Balance-sheet Equity And Moderate LeverageA moderate debt profile and stable equity ratio provide financial flexibility to fund working capital and selective investments. This cushioning reduces solvency risk, enabling management to pursue growth or restructure operations without immediate refinancing pressure in the medium term.
Bears Say
Negative Net Income And ROEPersistent net losses and a negative ROE weaken retained earnings and reduce internal funding capacity. Over months this limits ability to self-fund product development or expand commercial coverage, forcing reliance on external financing or cost cuts that can constrain strategic initiatives.
Declining Free Cash FlowA 20% fall in free cash flow signals deteriorating cash generation after investing and operations. Sustained FCF decline raises liquidity pressure, constrains capital allocation, and increases vulnerability to demand shocks or cyclical lab spending over the next several months without corrective measures.
Weak Operating MarginsLow EBIT/EBITDA margins mean limited internal buffer to absorb cost inflation or invest in R&D and sales expansion. Without margin improvement, profitability is fragile and scaling revenue may not translate into sustainable earnings, pressuring returns and cash conversion in the medium term.
Trajan Group Holdings Ltd News
TRJ FAQ
What was Trajan Group Holdings Ltd’s price range in the past 12 months?
Trajan Group Holdings Ltd lowest share price was AU$0.19 and its highest was AU$0.97 in the past 12 months.
What is Trajan Group Holdings Ltd’s market cap?
Trajan Group Holdings Ltd’s market cap is AU$31.34M.
When is Trajan Group Holdings Ltd’s upcoming earnings report date?
Trajan Group Holdings Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 61 days.
How were Trajan Group Holdings Ltd’s earnings last quarter?
Trajan Group Holdings Ltd released its earnings results on Feb 25, 2026. The company reported AU$0.005 earnings per share for the quarter, beating the consensus estimate of -AU$0.004 by AU$0.009.
Is Trajan Group Holdings Ltd overvalued?
According to Wall Street analysts Trajan Group Holdings Ltd’s price is currently Undervalued.
Does Trajan Group Holdings Ltd pay dividends?
Trajan Group Holdings Ltd does not currently pay dividends.
What is Trajan Group Holdings Ltd’s EPS estimate?
Trajan Group Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trajan Group Holdings Ltd have?
Trajan Group Holdings Ltd has 152,863,630 shares outstanding.
What happened to Trajan Group Holdings Ltd’s price movement after its last earnings report?
Trajan Group Holdings Ltd reported an EPS of AU$0.005 in its last earnings report, beating expectations of -AU$0.004. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of Trajan Group Holdings Ltd?
Currently, no hedge funds are holding shares in AU:TRJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trajan Group Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.83 (111.54% Upside)
AU$0.83 (111.54% Upside)
Insider Transactions
Bought Shares
Worth AU$7.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.50%
12-Months-Change
Fundamentals
Return on Equity
-1.32%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Trajan Group Holdings Ltd
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.
TRJ Stock 12 Month Forecast
Average Price Target
AU$0.83
▲(111.54% Upside)
Technical Analysis
Austco Healthcare Limited
―
Cyclopharm Limited
―
Singular Health Group Ltd
―
EZZ Life Science Holdings Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---








